Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RPL554 PK in Cystic Fibrosis
NCT02919995Phase 2Completed
- Sponsor
- Verona Pharma
- Start
- Feb 2017
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ensifentrine in cystic fibrosis (CF) (3 arms), sponsored by Verona Pharma. Primary endpoints: Area Under the Curve, Maximum Plasma Concentration and 2 more. Started Feb 2017; status: completed.
02
Drugs
ensifentrine
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02919995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02919995.